Abstract: Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.

Abstract: The present invention relates to a process for in situ the preparation of mixtures of chelating agents by catalyzed reactions of diethanolamine derivatives with maleic acid and then with 2-halocarboxylic acid, to mixtures of chelating agents and methods using such chelating agents.

Abstract: A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.

Abstract: Described herein are polymeric aminoacrylates formed by the reaction of polyalkylene glycol diacrylates with bireactive amines. The polymeric aminoacrylate are comprised of moieties of poly(alkylene glycol) diacrylate and moieties of bireactive amines. Also described herein are energy curable ink and coating compositions that include the described polymeric aminoacrylates. The energy curable ink and coating compositions that include the described polymeric aminoacrylates are well-suited for use in packaging applications where low migration of uncured monomer material after cure is desired, such as in the packaging of foodstuffs, pharmaceuticals, etc.

Abstract: A process for the preparation of a solid composition of an amino acid diacetic acid compound wherein the amino acid diacetic acid compound is methyl glycine-N,N-diacetic acid or a salt thereof, or glutamic N,N-diacetic acid or a derivative thereof, as well as the product obtained by such process are disclosed. The process includes feeding a saturated or oversaturated aqueous composition of the amino acid diacetic acid compound in an aqueous solvent to a drum dryer, wherein the aqueous composition is fed to the drum surface with a layer thickness of from about 0.1 to about 10 mm, the drum has a surface temperature of from about 80 to about 180° C., and the drum operates at a tangential speed of from about 0.1 to about 100 m/min. The method further includes removing the mass from the drum before a full revolution of the drum.

Abstract: A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.

Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?-, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.

Abstract: A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provided that the administration is carried out after a waiting period that follows administration of a compound including a radionuclide to the patient, the compound having affinity for both a cancerous tissue and the non-cancerous tissue, and, further provided that the binding sites have an affinity for both the agent and the compound.

Abstract: The present invention provides bivalent and multivalent ligands with a view to improving the affinity and pharmacokinetic properties of a urea class of PSMA inhibitors. The compounds and their synthesis can be generalized to multivalent compounds of other target antigens. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors. The modular multivalent scaffolds of the present invention, in one or more embodiments, contains a lysine-based (?, ?-) dialkyne residue for incorporating two or more antigen binding moieties, such as PSMA binding Lys-Glu urea moieties, exploiting click chemistry and one or more additional lysine residues for subsequent modification with an imaging and/or therapeutic nuclides or a cytotoxic ligands for tumor cell killing.

Abstract: The present invention relates to surface modified organic black pigments, surface modified carbon blacks, pigment mixtures and dispersions formed with these pigments, curable compositions, black matrices, and products incorporating them. The surface modified organic black pigment can have attached at least one organic group having the formula -X-Z, wherein X, which is directly attached to the pigment, represents an arylene group, a heteroarylene group, an alkylene group, an aralkylene group, or an alkarylene group, and Z represents at least one ionic group, at least one ionizable group, at least one nonionic group, at least one polymeric group, or any combinations thereof. Also disclosed are carbon black pigment combinations with the surface modified organic black pigments, low dielectric black dispersions, films, and black matrices containing them. Methods of preparing and making these various materials also are provided.

Abstract: The present invention relates to a process for the preparation of a mixture of aspartic acid diethoxy succinate and an amino acid derivative of the general formula (I) wherein n is 1-10, m is 0 or 1, and R is hydrogen or an alkali metal or alkaline earth metal ion, comprising reacting maleate with diethanol amine under alkaline conditions in the presence of a lanthanoid catalyst to form aspartic acid diethoxy succinate followed by adding aspartic acid which reacts with unreacted maleate to form imino disuccinic acid, i.e. an amino acid derivative of formula (I) wherein m is 0, or by adding a diamine derivative of the general formula (II) NH2(CH2)nNH2 wherein n is as defined above, which reacts with unreacted maleate to form an amino acid derivative of formula (I) wherein m is 1 and n is as defined above.

Abstract: The present invention relates to a method for recovering lanthanoid catalyst from the preparation of aspartic acid diethoxy succinate comprising contacting a carbonate source with a solution containing lanthanoid ions derived from said preparation and a chelating agent different from aspartic acid diethoxy succinate to precipitate lanthanoid carbonate followed by separating the precipitated lanthanoid carbonate from the solution.

Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.

Abstract: The instant invention provides for novel cationic lipids of Formula A that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.

Abstract: Provided is a lithium secondary cell which has high capacity, suppresses deterioration in capacity and improves cycle characteristics particularly when used in high-temperature environments and has long lifespan. Provided is a lithium secondary cell including a positive electrode active material layer containing a positive electrode active material, a negative electrode active material layer containing a negative electrode active material and an electrolytic solution for immersing the positive and negative electrode active material layers, wherein the electrolytic solution contains at least one certain ester compound.

Abstract: The invention relates to a method for the synthesis of a compound according to formula I comprising the following steps: a) reacting a Dane salt according to formula II and a Dane salt according to formula III with a coupling reagent; b) adding a diamine according to formula IV to the reaction mixture; and c) adding an acid to the reaction mixture to adjust the pH value of the reaction to <7; wherein L represents a C2-C20 alkyl group, a C6-C20 aryl group, or a C7-C20 alkylaryl group; R1 and R2 can be identical or different and represent a hydrogen atom, a C1-C4 alkyl group, a C1-C4 hydroxyalkyl group, a C1-C4 thioether group, a C6-C20 aryl group, a C7-C26) alkylaryl group, a C7-C20 alkylhydroxyaryl group, a C4-C20 alkylheteroaryl group with 1 to 4 heteroatoms; or a C1-C4 alkylcarboxylic moiety, which may be an acid, an amide, or which may be esterified with a C1-C6 alkyl group or a C7-C20 alkylaryl group; R3 represents a C1-C4 alkyl group; R4 represents a hydrogen atom, or a C1-C4 alkyl group; R5 represent

Abstract: A composition having a structure of: X-L-Y wherein X comprises at least one embelin moiety; L comprises a linker; and Y comprises a hydrophilic moiety. Also disclosed is a micelle that includes: a core that includes at least one hydrophobic active agent and at least one embelin moiety; and a hydrophilic zone surrounding the core and comprising at least one hydrophilic moiety.

Abstract: The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: An aqueous solution containing 0.1-20 wt % of a substituted choline or thiocholine hydroxide is a useful developer for photosensitive resist materials. A resist pattern is formed by applying a chemically amplified positive resist composition onto a substrate to form a resist film, exposing the resist film to high-energy radiation, and developing the exposed resist film in an ammonium hydroxide-containing aqueous solution.

Abstract: Methods of making monomethyl fumarate, which can then also be used in methods of making prodrugs of monomethyl fumarate, are disclosed. Monomethyl fumarate and prodrugs of monomethyl fumarate are useful for treating neurodegenerative, inflammatory, and autoimmune diseases including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

Abstract: Compounds containing at least one perfluoropolyether segment and at least two oxalylamino groups as well as methods of making these compounds are described. The compounds can be polymeric materials or can be used in the preparation of various copolymeric materials by reaction with compounds having at least two primary or secondary amino groups.

Abstract: The present invention relates to a compound of a formula (I) in which R1, R2, R3 are respectively independent equal or various organic radicals that have no Zerewitinoff active hydrogen, R4 are independently hydrogen, equal or different organic radicals, having no Zerewitinoff active hydrogen, or together form an unsaturated or aromatic ring, which can potentially contain heteroatoms, wherein R4 have no Zerewitinoff active hydrogen, X is a linear or branched, potentially even a substituted organic radical in the chain with heteroatom, which does not have Zerewitinoff active hydrogen, n 0<n?2 and m 0?m<2, wherein n+m=2. The invention also relates to a process for producing a compound of said formula (I) as well as a polyurea system containing such a compound.

Abstract: The invention relates to enantiomerically pure DOTAP chloride and stable crystal modifications of (2R,S)-, (2S)- and (2R)-DOTAP chloride, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.

Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

Abstract: A particulate material for the production of a cement foam which material includes particles including, attached to the particle surface, a surfactant which renders the particles hydrophilic, the surfactant including a moiety which is hydrolysable under alkaline conditions, which surfactant, after loss of the moiety by alkaline hydrolysis, renders the particles partially hydrophobic.

Abstract: This invention relates to novel precursors suitable for 18F radiolabeling of glutamate derivatives, methods for preparing such compounds and its intermediates, compositions comprising such compounds, kits comprising such compounds or compositions and methods for 18F radiolabeling of glutamate derivatives wherein the obtained 18F radiolabeled glutamate derivatives are suitable for diagnostic imaging by Positron Emission Tomography (PET) of proliferative diseases e.g. tumor in mammals.

Abstract: A multifunctional polymerizable ionic liquid is described comprising an anion and a cationic group having at least two ethylenically unsaturated polymerizable groups, each bonded to the cationic group via a divalent non-alkyl linking group. The multifunctional linking groups independently comprise a heteroatom such as oxygen or nitrogen. The linking groups may independently comprise one or more linkages such as an amide, urea, and more typically a urethane or ester linkage. The ethylenically unsaturated polymerizable groups are typically (meth)acrylate groups. Coatings and coated articles are also described.

Abstract: Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA.

Abstract: A process is proposed for the preparation of a powder comprising one or more derivatives of glycine-N,N-diacetic acid and/or one or more derivatives of glutamine-N,N-diacetic acid with a degree of crystallinity of a ?30%, starting from an aqueous solution comprising the one or more derivatives of glycine-N,N-diacetic acid and/or the one or more derivatives of glutamine-N,N-diacetic acid in a concentration range from 20 to 60% by weight, based on the total weight of the aqueous solution, where the aqueous solution is concentrated in a first process step in an evaporator with rotating internals, which are arranged at a distance relative to the inside wall of the evaporator of ?1% of the diameter of the evaporator, to give a crystal slurry with a solids concentration in the range from 60 to 85% by weight, based on the total weight of the crystal slurry, and where in a second process step the crystal slurry is left to ripen in a paste bunker and then in a thin-film contact dryer, and where the residence time i

Abstract: A method of preparing a lubricating oil additive composition comprising reacting (A) a nitrogen-containing reactant derived from reacting a first reaction product with a triglyceride, wherein the first reaction product is derived by reacting an alkanolamine and a base, wherein the nitrogen-containing reactant comprises three equivalents of a nitrogen-containing compound and one equivalent of glycerol, and wherein the nitrogen-containing reactant contains less than 10 mass percent of glycerol alkyl ester; (B) a source of boron; and (C) glycerol.

Abstract: Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the formula: wherein R is selected from one or more of the same or different of hydrogen, hydroxyl, optionally substituted alkyl, optionally substituted aryl, alkoxy, aryloxy, thiol, and optionally substituted amino, and wherein R1 is selected from one or more of the same or different of hydrogen, acetyl, optionally substituted alkyl, optionally substituted aryl, and an amino acid selected from leucine, valine, isoleucine, and glycine.

Abstract: A compound represented by the following general formula (1), and a method for producing the compound represented by the general formula (1), the method comprising: reacting together a compound represented by the following general formula (2), a compound represented by the following general formula (3), and a compound represented by the following general formula (4): wherein R1 represents any of a protective group of a carboxyl group, and a hydrogen atom, R2 and R3 each independently represent any of a protective group of an amino group, and a hydrogen atom, and R4 represents any of a protective group of a carboxyl group, and a hydrogen atom.

Abstract: The present invention relates to a chelating agent precursor that contains glutamic acid N,N-diacetic acid (GLDA) and/or methylglycine N,N-diacetic acid (MGDA) wherein at least one of the carboxylic acid groups is present as a carboxylic acid derivative selected from the group of amides, anhydrides, and esters, combinations thereof, and salts thereof, provided that it is not the triethyl ester of GLDA, the triethyl mono-t-butyl ester of GLDA, the tri-t-butyl ester of GLDA, the monobenzyl tri-t-butyl ester of GLDA, any ester or amide that contains azacycloalkane groups, any amide that contains biotin groups, any amide that contains minoethylcarbamoyl based amide groups, (S)-diethyl 2,2?-(1-benzyloxy)-1,5-dioxo-5-(prop-2-ynylamino)pentan-2-ylazanediyl-diacetate, diethyl 2,2?-(5-(3-azidopropylamino)-1-(benzyloxy)-1,5-dioxo-pentan-2-ylazanediyl-diacetate, the trimethyl ester of MGDA, the monomethyl ester dimethylamide of MGDA, the dibenzyl ester of MGDA, the dibenzyl mono t-butyl ester of MGDA, the di t-butyl est

Abstract: The present invention provides an inexpensive and industrially advantageous method for producing an optically active form of an anti-(3S,4R)-3-alkylcarbamoyl-4-hydroxypyrrolidine derivative or it's enantiomer, which is a key intermediate for producing a high-quality optically active form of (3R,4S)-3-alkylaminomethyl-4-fluoropyrrolidine or it's enantiomer useful as an intermediate for producing pharmaceuticals. The present invention relates to a method for producing an optically active anti-(3S,4R)-4-hydroxypyrrolidine-3-carboxamide derivative, or it's enantiomer by carrying out asymmetric hydrogenation using an optically active catalyst of a 4-oxopyrrolidine-3-carboxamide derivative represented by the general formula (I). [in the formula (I), PG1 represents a protective group for an amino group, and R1 represents hydrogen, a C1 to C6 alkyl group which may be substituted, or a C3 to C8 cycloalkyl group which may be substituted].

Abstract: A positive resist composition comprising (A) a compound capable of generating an acid upon irradiation with an actinic ray or radiation, (B) a resin capable of increasing the solubility in an alkali developer by the action of an acid, and (C) a compound having a specific structure, which decomposes by the action of an acid to generate an acid, a pattern forming method using the positive resist composition, and a compound for use in the positive resist composition are provided as a positive resist composition exhibiting good performance in terms of pattern profile, line edge roughness, pattern collapse, sensitivity and resolution in normal exposure (dry exposure), immersion exposure and double exposure, a pattern forming method using the positive resist composition and a compound for use in the positive resist composition.

Abstract: The present invention relates to a process for the preparation of a mixture of aspartic acid diethoxy succinate and an amino acid derivative of the general formula (I) wherein n is 1-10, m is 0 or 1, and R is hydrogen or an alkali metal or alkaline earth metal ion, comprising reacting maleate with diethanol amine under alkaline conditions in the presence of a lanthanoid catalyst to form aspartic acid diethoxy succinate followed by adding aspartic acid which reacts with unreacted maleate to form imino disuccinic acid, i.e. an amino acid derivative of formula (I) wherein m is 0, or by adding a diamine derivative of the general formula (II) NH2(CH2)nNH2 wherein n is as defined above, which reacts with unreacted maleate to form an amino acid derivative of formula (I) wherein m is 1 and n is as defined above.

Abstract: The present invention relates to a method for recovering lanthanoid catalyst from the preparation of aspartic acid diethoxy succinate comprising contacting a carbonate source with a solution containing lanthanoid ions derived from said preparation and a chelating agent different from aspartic acid diethoxy succinate to precipitate lanthanoid carbonate followed by separating the precipitated lanthanoid carbonate from the solution.

Abstract: Disclosed are halogenated amide esters that are suitable as internal electron donors in procatalyst compositions. Ziegler-Natta catalyst compositions containing the present procatalyst compositions exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.

Abstract: Disclosed are creatine ?-alaninate, compositions and formulations containing same, and methods of use therefor.

Abstract: The present invention relates to a cosmetic composition containing a combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, especially corresponding to one of the formulae (I) or (II) below: in which at least one or two of the radicals contain: either an alkylsulfonate radical in its acid or salified form, or one or two hydroxyl radicals. The invention also relates to a process for the radiation-photostabilization of at least one screening agent of the dibenzoylmethane derivative type with an effective amount of at least one particular hydrophilic or water-soluble merocyanin UV-screening agent, especially corresponding to one of the formulae (I) or (II).

Abstract: The invention relates to enamine resins which are the reaction products of a) an acetoacetylated resin, and a C1-C20 alkyl amine or a mixture of C1-C20 alkyl amines. The acetoacetylated resin is the reaction product of a polyol having 4 or more hydroxyl groups; and at least one acetoacetate. The invention also relates to an acetoacetylated resin which is the reaction product of a polyol having 4 or more hydroxyl groups and at least one acetoacetate, where a portion of the hydroxyl groups of the polyol are replaced by acetoacetate groups and the remaining hydroxyl groups are replaced by a saturated monofunctional carboxylic acid ester, unsaturated monofunctional carboxylic acid ester, or a mixture thereof; as well as to enamine resins prepared from these acetoacetylated resins. The invention also relates to curable coating compositions containing such resins or a mixture of those resins, at least one metallic drier compound; and optionally one or more solvents.

Abstract: What is proposed is a process for preparing aminopolycarboxylates proceeding from the corresponding polyalkanolamines by oxidative dehydrogenation in the presence of a catalyst comprising 1 to 90% by weight of copper, based on the total weight of the catalyst, using a base, which comprises first performing a partial conversion of the polyalkanolamine to a reaction mixture comprising the aminopolycarboxylate at a temperature in the range from 140 to 180° C. until at least 10 to 90 mol % of the polyalkanolamine has been depleted, and then continuing the conversion at elevated temperature.

Abstract: Compounds containing at least one perfluoropolyether segment and at least two oxalylamino groups as well as methods of making these compounds are described. The compounds can be polymeric materials or can be used in the preparation of various copolymeric materials by reaction with compounds having at least two primary or secondary amino groups.

Abstract: D-aspartic acid is prepared as its hydrochloride salt or as the hydrochloride salt of its diethyl ester, thereby providing soluble forms of D-aspartic acid that are readily taken up by a human body via its digestive tract. The D-aspartic acid is administered as pills, capsules, powdered drink mixes, beverages, confectionaries, syrups, chewable tablets, nasal sprays, or injectable formulations.

Abstract: The present invention relates to new classes of monomeric compounds, which may be polymerized to form novel biodegradable and bioresorble polymers and copolymers. These polymers and co-polymers, while not limited thereto, may be adapted for radio-opacity and are useful for medical device applications and controlled release therapeutic formulations.

Abstract: The present invention relates to the novel compounds of the formula (I), as well as to their manufacture and use and compositions comprising them. The invention also relates to a change in oxidation reactions of hydrocarbons admixed to these compounds. Furthermore the invention relates to (bio)diesel fuel comprising such compounds.

Abstract: The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.

Abstract: Crosslinked polymers, methods for their preparation and use, are described in which the crosslinked polymers are formed from at least two polymer precursors, one of which is designed, upon degradation of the crosslinked polymer, to release the second polymer precursor in its original, unmodified chemical form.

Abstract: In various embodiments, the present disclosure describes fullerene derivatives that are capable of photocatalytically generating reactive oxygen species in the presence of ultraviolet and/or visible light. In some embodiments, the fullerene derivatives are aminofullerenes containing a plurality of amine-terminated moieties covalently bonded to the fullerene cage. The fullerene derivatives may optionally be covalently bonded to a substrate surface for use in photocatalytic disinfection systems for removing various contaminants including, for example, bacteria, viruses, protozoa and chemical pollutants. Methods using the present fullerene and aminofullerene derivatives in various purification processes are also described herein.

Abstract: A compound represented by the following formula (a): CH2?CR1—CONJ-CKR2—(CH2)n—COO-Q1-Rf1??(a) is provided. This compound is capable of forming a polymer having an oil repellency equivalent to polymers containing a polyfluoroalkyl group containing at least 8 carbon atoms, although the polyfluoroalkyl group contains up to 6 carbon atoms. In the formula, R1 is hydrogen atom or methyl group, R2 is hydrogen atom or a group represented by —(CH2)m—COO-Q2-Rf2 (r), n and m are independently an integer of 0 to 4, Rf1 and Rf2 are independently a polyfluoroalkyl group or a polyfluoroether group containing 1 to 6 carbon atoms, Q1 and Q2 are independently single bond or a divalent linkage group, J is hydrogen atom or an alkyl group containing 1 to 3 carbon atoms, K is hydrogen atom or an alkyl group containing 1 to 3 carbon atoms, and j and k are independently single bond or an alkylene group containing 1 to 3 carbon atoms with the proviso that j and k are not simultaneously single bond.